Available EXPANDED_ACCESS NCT07119775
Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
Sponsor: AMO Pharma Limited
Conditions
Congenital Myotonic Dystrophy
Interventions
Tideglusib
Updated 1 time since 2025 Last updated: Aug 6, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A observational or N/A phase clinical study on Congenital Myotonic Dystrophy, this trial is ongoing. The trial is conducted by AMO Pharma Limited and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Available
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- AMO Pharma Limited
Data source: AMO Pharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.